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Abstract
Background: Primary cutaneous melanoma of the breast is a very rare tumour, accounting for <
5% of all malignant melanomas.
Case presentation: A young lady was seen in the breast clinic for a skin lesion in the right breast.
Clinical examination and investigations confirmed a diagnosis of a primary cutaneous melanoma of
the breast. The lesion was excised and the patient made good recovery. She has shown no signs of
local recurrence and is under regular follow-up in the dermatology clinic.
Conclusion: This case is educational as it shows that the treatment of breast cutaneous melanoma
is similar to that for any skin parts with surgery remaining the main therapeutic option. It also shows
that mastectomy is unnecessary as it does not improve the results obtained by wide local excision
of melanoma.
Background
Primary cutaneous melanoma rarely affects the breast,
accounting for less than 5% of all malignant melanomas.
Operable cutaneous melanomas are treated with wide
local excision. The presence or absence of metastases in
the regional lymph nodes (RLN) is the most significant
prognostic variable that predicts survival in patients with
melanomas.
Case presentation
A 22 years-old female was assessed in the breast clinic in
November 2004 for a right breast skin lesion which had
been present for about a year. It had increased in size and
occasionally bled. She is non smoker and has no signifi-
cant past breast history. There is no family history of
breast cancer.
Examination revealed a 5 mm mole on the right areola
without any associated breast lumps or palpable axillary
lymph glands. No organomeagaly was noted on abdomi-
nal examination. Excision of the mole under a local anaes-
thetic in January 2005, showed it to be a superficial
spreading malignant melanoma with a tumour thickness
of 0.5 mm, corresponding to pT1, Clarke level II (Figure
1). Minimum lateral clearance was 1 mm with a 4 mm
deep clearance. CT of abdomen and chest excluded the
presence of a metastatic disease. She underwent wider
excision but no residual disease was found, and it also
resulted in a clearance margin of more than 1 cm. Twelve
months post surgery, she remains well in herself under the
care of the dermatologists without any signs of recurrent/
metastatic disease.
Discussion
Primary cutaneous melanoma rarely affects the breast,
accounting for less than 5% of all malignant melanomas
[1,2]. Several cases have been reported in the literature
[2,3]. It is highly probable that there is no significant dif-
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ference between melanomas of the breast and melanomas
arising from other cutaneous areas as far as correlation of
Clark's level of invasion with prognosis and regional
lymph node status is concerned [1,3]. In general, operable
cutaneous melanomas are treated with wide local exci-
sion. 1 cm clearance is adequate for lesions < 1 mm thick
and a 2 cm margin for lesions up to 4 mm thick [4]. There
are few data to support the use of margins wider than 2
cms even in lesions > 4 mm thick [5]. In our case the radial
margin of over 1.0 cm was adequate as the lesion was < 1
mm thick. The presence or absence of metastases in the
regional lymph nodes (RLN) is the most significant prog-
nostic variable that predicts survival in patients with
melanomas. It is extremely rare for it to spread systemi-
cally without first passing through the first draining
lymph node basin [6]. These neoplasia are felt to follow a
different metastatic pattern than do primary carcinoma of
the breast, and require a different therapeutic approach
[3].
Papachristuo et al [3] found that lesions located below a
3 cm radius from the clavicle metastasised exclusively to
the axillary lymph nodes regardless of sex or location. Fur-
ther, in their 19 patients with central and medial lesions
where internal mammary nodes were available for exami-
nation, none of them had disease in those nodes despite
the fact that half of them had simultaneous axillary node
metastases. Where the RLN are impalpable, their surgical
assessment has been controversial and has varied from
selective lymph node dissection to elective lymph node
dissection (ELND). A major argument against ELND in all
is that if all patients with high risk melanomas are sub-
jected to ELND, 70–80% will receive an unnecessary sur-
gical procedure as only 20–30% will have RLN
metastases. The therapeutic benefit of removing clinically
normal nodes has never been proven [7,8]. Patients with
thick melanomas (> 4.0 mm) have a high incidence of sys-
temic disease and should undergo a proper extent of dis-
ease evaluation. Regional node assessment provides
valuable staging and prognostic information [4], and for
lesions located 3 cm from the clavicle [3], nodal assess-
ment on the cervical region has been recommended.
Assessment of regional nodes was not necessary in our
case as the tumour was < 1 mm thick. Just over a decade
ago regional nodes were assessed by complete lymph
node dissection (CLND) [6] resulting in unnecessary sur-
gery in many [9,10]. However, the introduction of senti-
nel lymph node biopsy(SNLB) into surgical practice has
revolutionized the assessment of regional nodes [10].
Morton and colleagues were the first to demonstrate that
lymphatic drainage from a melanoma can be "mapped"
by injecting the skin around the tumour with blue
dye[10]. Injected blue dye was shown to travel through
lymphatic channels to the first, or "sentinel" lymph node
(SLN) that drains the tumour. It was shown that histolog-
ical examination of the SLN accurately reflected the path-
ological status of the entire regional lymph node basin. A
positive SLN is associated with a higher chance of the
remaining nodes containing metastases, while patients
with negative SLNs infrequently have other nodes that
contain tumour cells [9,10]. SLN mapping, therefore,
spares approximately 80–85% of patients with melanoma
from having CLND for what will ultimately be a negative
regional nodal basin [9,10].
Patients with melanomas most likely to benefit from
SLNB have thickness of 1–4 mm [10] as the incidence of
nodal metastases ranges from 6% for patients with 1 mm
melanomas to 35% in patients with 4 mm melanomas
[10,11]. For patients with melanomas less than 1 mm, the
indications for SLNB would be Clark level IV depth, pres-
ence of tumour regression, and ulceration [12]. Young
age, higher number of mitoses, male gender and axial
location are viewed as some of the relative indications
[13]. The third interim analysis of the Multicentre Selec-
tive Lymphadenectomy Trial (MSLT-1) on SLNB shows
that melanoma patients who had wide excision followed
by selective lymph node dissection had a survival similar
to patients where a watch and wait policy had been fol-
lowed, with complete lymph node dissection in case of
pathological lymph node involvement. In this study the
disease free survival was superior after SLNB [14].
Conclusion
Treatment of breast cutaneous melanoma is the same as
that for any skin parts. Surgery remains the most impor-
tant therapeutic modality particularly in preventing local
recurrence. Mastectomy does not improve the results
obtained by wide excision of the primary melanoma.
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SLNB, with tremendous benefits and minimal risk, is
becoming widely adopted as most surgeons who treat
breast cancer and melanoma incorporate this technique
into their practice.
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